Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27455401 | 0.86 | TSHR (0.68) | ALDH1A1TSHRCYP1A2TDP1MAPT | |
| SCHEMBL20921370 | 0.86 | ALDH1A1 (0.47) | ALDH1A1TSHRCYP1A2TDP1MAPT | |
| SCHEMBL3323932 | 0.85 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP1A2TDP1MAPT | |
| SCHEMBL11254195 | 0.84 | CYP1A2 (0.50) | ALDH1A1TSHRCYP1A2TDP1HSD17B10 | |
| SCHEMBL16674748 | 0.84 | ALDH1A1 (0.49) | ALDH1A1TSHRCYP1A2TDP1MAPT | |
| SCHEMBL23861299 | 0.84 | ALDH1A1 (0.49) | ALDH1A1TSHRCYP1A2TDP1HSD17B10 | |
| SCHEMBL992973 | 0.84 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP1A2TDP1HSD17B10 | |
| SCHEMBL29695357 | 0.84 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP1A2TDP1HSD17B10 | |
| SCHEMBL7777994 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP1A2TDP1HSD17B10 | |
| SCHEMBL6680574 | 0.83 | ALDH1A1 (0.45) | ALDH1A1TSHRCYP1A2TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11191752-B2 | Compounds and methods of treating retinal degeneration | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200230119-A1 | COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION | CASE WESTERN RESERVE UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
| US-9670198-B2 | Nicotinic acetylcholine receptor modulators | ASTRAEA THERAPEUTICS, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9598713-B2 | Method for constructing functional nucleic acid molecule, and nucleic acid combination to be used in said method | JAPANESE SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20150118713-A1 | METHOD FOR CONSTRUCTING FUNCTIONAL NUCLEIC ACID MOLECULE, AND NUCLEIC ACID COMBINATION TO BE USED IN SAID METHOD | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2015-04-30 | — | — | US | disclosed |
| WO-2012018662-A2 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | SCHERING CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-5711020-A | BIODEGRADATION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ENVIRONMENTAL PROTECTION AGENCY (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0034292-B1 | PROCESS FOR THE PREPARATION OF ANTHRANILIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-11-23 | — | — | EP | disclosed |
| EP-0034292-A2 | Process for the preparation of anthranilic acid derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200230119-A1 | COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION | PDE6A, PDE6H, PDE6D | ALDH1A1 1072/4885TSHR 2386/4885CYP1A2 3645/4885 |
| US-11191752-B2 | Compounds and methods of treating retinal degeneration | PDE6A, PDE6H, PDE6D | ALDH1A1 1072/4885TSHR 2386/4885CYP1A2 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.